Genmab AS【GMAB】銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

20.875

買値

20.87

売値

20.88

出来高

324,304

20.70 日の範囲 20.875

0.00 52 週間の範囲 0.00

時価総額

13.793B

前日終値

21.02

始値

20.805

時刻

20.875

最終取引時間

02:48:14

財務取引量

US$ 6,742,873

VWAP

20.7918

平均取引量 (3 か月)

発行済株式数

660,745,350

配当利回り

PER

30.65

1 株当たり利益 (EPS)

6.59

歳入

16.47B

純利益

4.35B

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the stan... Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered wth Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications. 詳細を表示

セクター

Biological Pds,ex Diagnstics

業界

Biogenetic (human)

ウェブサイト

www.genmab.com

本社

Copenhagen, Dnk

設立

2000

Genmab AS is listed in the Biological Pds,ex Diagnstics sector of the ナスダック市場 with ticker GMAB. The last closing price for Genmab AS was US$21.02. Over the last year, Genmab AS shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Genmab AS currently has 660,745,350 shares in issue. The market capitalisation of Genmab AS is US$13.89 billion. Genmab AS has a price to earnings ratio (PE ratio) of 30.65.

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Results from Arm 1 of the EPCORE® NHL-2 trial show treatment with epcoritamab combination led to an overall response rate (ORR) of 100 percent and a complete response (CR) rate of 87 percent in...

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Genmab A/S (Nasdaq: GMAB): Preliminary analyses from the EPCORE® CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily...

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Genmab A/S (Nasdaq: GMAB): Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and 80 percent 21-month progression-free survival (PFS) in patients with...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

Genmab A/S (Nasdaq: GMAB): More than 20 abstracts, including four oral presentations, with new clinical data across lines of therapy and subgroups of non-Hodgkin’s lymphoma (NHL) patients New...

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion cohort Responses with Rina-S were observed...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

GMAB - Frequently Asked Questions (FAQ)

What is the current Genmab AS share price?

The current share price of Genmab AS is US$ 20.875

How many Genmab AS shares are in issue?

Genmab AS has 660,745,350 shares in issue

What is the market cap of Genmab AS?

The market capitalisation of Genmab AS is USD 13.89B

What is the 1 year trading range for Genmab AS share price?

Genmab AS has traded in the range of US$ 0.00 to US$ 0.00 during the past year

What is the PE ratio of Genmab AS?

The price to earnings ratio of Genmab AS is 30.65

What is the cash to sales ratio of Genmab AS?

The cash to sales ratio of Genmab AS is 8.1

What is the reporting currency for Genmab AS?

Genmab AS reports financial results in DKK

What is the latest annual turnover for Genmab AS?

The latest annual turnover of Genmab AS is DKK 16.47B

What is the latest annual profit for Genmab AS?

The latest annual profit of Genmab AS is DKK 4.35B

What is the registered address of Genmab AS?

The registered address for Genmab AS is KALVEBOD BRYGGE 43, COPENHAGEN, 1260

What is the Genmab AS website address?

The website address for Genmab AS is www.genmab.com

Which industry sector does Genmab AS operate in?

Genmab AS operates in the BIOGENETIC (HUMAN) sector

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
NXUNXU Inc	US$ 1.885 (674.45%)	466.66M
WATTEnergous Corporation	US$ 1.485 (261.14%)	168.7M
INTZIntrusion Inc	US$ 5.35 (147.69%)	115.82M
SMXSMX Security Matters Public Company	US$ 0.8276 (134.05%)	177.94M
JDZGJIADE Ltd	US$ 1.49 (112.80%)	8.81M
ABPAbpro Holdings Inc	US$ 2.20 (-51.00%)	1.54M
TRAWTraws Pharma Inc	US$ 7.72 (-42.47%)	931k
SHOTWSafety Shot Inc	US$ 0.13 (-27.90%)	1.25k
LITMSnow Lake Resources Ltd	US$ 1.16 (-27.50%)	46.21M
BITSGlobal X Blockchain and Bitcoin Stratagy ETF	US$ 66.9375 (-24.33%)	9.39k
NXUNXU Inc	US$ 1.885 (674.45%)	466.66M
VINCVincerx Inc	US$ 0.3436 (77.11%)	308.08M
XTIAXTI Aerospace Inc	US$ 0.0399 (1.01%)	187.57M
SMXSMX Security Matters Public Company	US$ 0.8276 (134.05%)	177.94M
WATTEnergous Corporation	US$ 1.485 (261.14%)	168.7M